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ABSTRACT
Introduction: Methylphenidate is the most frequently
used medication for the treatment of attention-deficit/
hyperactivity disorder (ADHD) in Europe. Following
concerns about its safety, the European Commission
called for research into the long-term effects of
methylphenidate on children and adolescents with
ADHD. The Attention Deficit Hyperactivity Disorder
Drugs Use Chronic Effects (ADDUCE) research
programme was designed to address this call. At the
heart of this programme is a 2-year longitudinal
naturalistic pharmacovigilance study being conducted
in 27 European sites.
Methods and analysis: 3 cohorts of children and
adolescents (aged 6–17) living in the UK, Germany,
Italy and Hungary are being recruited:
Group 1 (Medicated ADHD): 800 ADHD medication-
naive children and adolescents with a clinical diagnosis
of ADHD about to start methylphenidate treatment for
the first time.
Group 2 (Unmedicated ADHD): 400 children and
adolescents with a clinical diagnosis of ADHD who
have never been treated with ADHD medication and
have no intention of beginning medication.
Group 3 (Non-ADHD): 400 children and adolescents
without ADHD who are siblings of individuals in either
group 1 or 2.
All participants will be assessed 5 times during their 2-
year follow-up period for growth and development,
psychiatric, neurological and cardiovascular health. The
primary outcome measure will be the height velocity
SD score.
Ethics and dissemination: Ethical approval for the
study has been granted by the East of Scotland
Research Ethics Service. Following this approval,
patient information leaflets and consent forms were
translated as necessary and submissions made by lead
sites in each of the other 3 countries to their own
ethics committees. Following ethical approval in each
country, local ethical permissions at each site were
sought and obtained as needed. The study’s website
Strengths and limitations of this study
▪ The Attention Deficit Hyperactivity Disorder Drugs
Use Chronic Effects (ADDUCE) will provide long-
term pharmacovigilance data about methylphenid-
ate use in children and adolescents with attention-
deficit/hyperactivity disorder (ADHD).
▪ In particular, the study will provide information
about the effects of methylphenidate on growth
and development, psychiatric health, neurological
health, cardiovascular function.
▪ The study includes two control groups: one of
children and adolescents with ADHD who are
unmedicated, and one of children and adoles-
cents without ADHD.
▪ Owing to its naturalistic design, participants are
not randomised to a particular group and there
is no placebo-control group in the design.
▪ The number and type of assessments that we
wished to conduct has to be balanced against the
time burden placed on our participants. Therefore,
while it would have been desirable to collect data
on cognitive testing, acceptability of the medica-
tion and quality of life, we were unable to fit these
tests into our assessment schedule.
▪ Although the European Union agreed that the
2-year follow-up described in this study fulfilled
their requirement for an investigation of the
‘long-term’ effects of methylphenidate, many
children and adolescents are prescribed the drug
for longer than this. If future funding is secured,
consent may be sought from some or all partici-
pants for additional, longer term follow-up.
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(http://www.adhd-adduce.org/page/view/2/Home) provides
information for researchers, participants and the general public.
Trial registration number: NCT01470261.
INTRODUCTION
Attention-deﬁcit/hyperactivity disorder (ADHD) is a
neurodevelopmental disorder characterised by core
symptoms of inattention, hyperactivity and impulsivity.1
The worldwide prevalence is estimated at 5.3% with a
prevalence for children around 6.5% and 2.7% for ado-
lescents with no signiﬁcant differences between Northern
America and Europe.2
The most commonly prescribed medication for the
treatment of ADHD in children and adolescents is
methylphenidate (MPH), a central nervous system psy-
chostimulant medication.3 4
The mechanism of action of psychostimulants is not
completely clear; however, it is believed that they inhibit
the reuptake of dopamine and norepinephrine into the
presynaptic neuron and/or increase their release into
extraneuronal space, thus increasing intrasynaptic con-
centrations.5 Randomised controlled trials of MPH have
established its efﬁcacy with around 70% of patients
responding positively, with improvements seen in many
areas including inattentiveness, impulsiveness, hyper-
activity and self-esteem.6
MPH has been available in the European Union (EU)
since the 1950s, and its use has increased markedly in
Western countries over the past decade. In England and
Wales, prescriptions for MPH rose to over 650 000 in
2012, a 56% rise since 2007,7 and a similar pattern of
growth in prescriptions has been evident in other
European countries such as Germany, Sweden,
Switzerland and Spain,8–11 the USA12 and Asia.13
Perhaps surprisingly for a drug so widely prescribed, the
adverse effect proﬁle of the drug is not fully charac-
terised. This is partly because the regulatory require-
ments for such information at the time the drug was
licensed were less stringent than those currently in
place. Much of the clinical research in this area has
focused on short-term efﬁcacy with trial designs often
limited by short experimental duration, small numbers
of patients and inappropriate control groups. This has
resulted in data sets with limited information on drug
tolerability and safety. Some of the data obtained by
these studies, together with spontaneous reports of
adverse events by marketing authorisation holders,
raised sufﬁcient concern over the safety of MPH that the
European Commission requested a community referral
to its Committee for Medicinal Products for Human Use
(CHMP) for all MPH-containing products in June
2007.14 Such referrals are initiated when there are con-
cerns relating to the protection of public health or
where other community interests are at stake.15 The
CHMP concluded in January 2009 that overall the
beneﬁt of MPH outweighs the risk when prescribed to
children with ADHD aged 6 years and over.16 However,
the Committee made recommendations to standardise
prescribing and provision of safety information across all
EU member states. Importantly, the report also stated
that more data are required on the long-term effects of
MPH on children and adolescents and concluded that
further research should be carried out to investigate
long-term effects of MPH on (1) growth and develop-
ment, (2) neurological health, (3) psychiatric health,
(4) sexual development and fertility and (5) cardiovas-
cular effects in adults who have taken/are taking
MPH.16 The CHMP emphasised the need for designs
that allow the comparison of exposed children with suit-
able control groups bearing in mind that ADHD covers
a broad spectrum of behaviour and may be associated
with other disorders. As a result of these recommenda-
tions for further research, the Fourth Call of the
European Commission’s Framework Programme (FP7)
invited proposals addressing the ‘long-term effects in
children and in young adults of MPH in the treatment
of ADHD’.17
To answer this call, the Attention Deﬁcit Hyperactivity
Disorder Drugs Use Chronic Effects (ADDUCE) consor-
tium was established, comprising experts in the ﬁelds of
ADHD, drug safety, neuropsychopharmacology and car-
diovascular research. It developed a programme of
research designed to ﬁll the identiﬁed gaps in the
current literature and to address the concerns of CHMP,
and it was funded in 2012.
The ADDUCE programme has a number of empirical
work packages (WPs).18 This paper focuses on the work
of WP 3, which is a 2-year prospective cohort study with
appropriate control groups that forms part of the
ADDUCE project and is designed to provide new data to
speciﬁcally answer the questions raised by CHMP about
long-term MPH safety in children and adolescents with
ADHD. This study is underway and data collection will
be completed in January 2016.
METHODS AND ANALYSIS
Objectives
ADDUCE WP 3 addresses scientiﬁc questions about
prevalence, clinical signiﬁcance, development and moder-
ating and/or mediating factors of four speciﬁc classes of
potential long-term adverse effects of MPH on growth,
neurological, psychiatric and cardiovascular health.
Evidence from observational studies providing longitu-
dinal data indicates that treatment with MPH may result
in a reduction in the rate of growth,19–23 in particular
during the ﬁrst year of treatment.20 There remain uncer-
tainties over whether any changes in height persist in
the long term, and whether changes are the result of
medication or whether ADHD itself is associated with
growth problems. In view of these uncertainties and
the clear importance of determining whether MPH
treatment does have effects on growth, the height vel-
ocity SD score (SDS) was chosen as the primary
outcome measure.
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While the height velocity SDS was chosen as the
primary outcome measure on which to base the sample
size, the study will collect data on other key outcomes in
the ﬁelds of growth, cardiovascular system, psychiatric and
neurological health. MPH acts primarily as a dopamine-
norepinephrine reuptake inhibitor by binding to and
blocking dopamine transporters24 and increased levels of
norepinephrine and dopamine can potentially affect the
cardiovascular system such as heart rate25 and the central
nervous system (CNS) system such as psychosis.26 The
effectiveness of MPH medication will also be assessed.
Study design
Design
The study is a 2-year naturalistic longitudinal prospective
pharmacovigilance multicentre study investigating the
long-term tolerability and safety of MPH in children and
adolescents aged between 6 and 17 years.
Cohorts
Three cohorts of children and adolescents (aged 6–17)
are being recruited from child and adolescent mental
health services in the UK, Germany, Italy and Hungary:
Group 1 (Medicated ADHD): comprises children and
adolescents with a clinical diagnosis of ADHD accord-
ing to Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM IV) criteria who have
not yet been medicated with any ADHD medication
and are about to start MPH treatment for the ﬁrst time.
Group 2 (Unmedicated ADHD): comprises children and
adolescents with a clinical diagnosis of ADHD accord-
ing to DSM IV criteria who have never been treated
with ADHD medication and for whom there is no
current intention of beginning treatment with ADHD
medication.
Group 3 (Non-ADHD): comprises children and adoles-
cents without ADHD who are siblings of individuals in
either group 1 or 2.
Eligibility criteria
The inclusion criteria are deliberately broad and the
exclusion criteria minimal. This is to ensure that the
study captures a typical group of patients with ADHD
presenting to clinical services throughout the EU and
that the results are applicable across Europe.
Participants eligible for group 1 or 2 must be diag-
nosed as having ADHD according to DSM IV criteria by
a qualiﬁed clinician according to normal clinical prac-
tice in each country. The diagnosis may take into
account reports from schools and carers.
Participants in group 3 must score less than 1.5 on the
Swanson Nolan and Pelham IV Rating scale (SNAP IV27)
for the ADHD items. Their hyperactivity score on the
parent-rated Strength and Difﬁculties Questionnaire
(SDQ28), should be within the normal range for their
country (eg, <6 for the UK). Full biological siblings are
preferred for this group, although half-siblings and sib-
lings not biologically related to the proband will also be
considered. A strict order of preference is deﬁned so
that older siblings of the same sex as the proband have
the highest preference, followed by younger siblings of
the same sex, older siblings of the opposite sex and
ﬁnally younger siblings of the opposite sex.
Participants are eligible if they are taking other psycho-
tropic drugs. A medication history is collected at each
study visit.
Enrolment
Participants eligible for groups 1 and 2 are identiﬁed by
the principal investigator or a designee who is experi-
enced in the evaluation of children and adolescents with
ADHD. Age-appropriate information about the study is
provided to the child/adolescent and parent/legal guard-
ian. If the participant is eligible and willing, a researcher
who has received Good Clinical Practice (GCP) and
consent training takes informed written consent from the
parent/legal guardian and assent from the participant.
Participants aged 16 or 17 years may provide their own
written consent, depending on the regulations of the
country in which they are recruited. The right of a child
or parent to refuse to participate is respected. Participants
are free to withdraw at any time during the study, and this
will not inﬂuence their clinical treatment. If a participant
withdraws during the assessment period, data collected up
until the point of withdrawal will remain in the study data-
base and be included in the ﬁnal analysis.
Siblings of participants enrolled into groups 1 and 2
are invited to participate in the study in group 3 and
given age-appropriate study information. If they are
willing to participate, they are asked to give written
consent/assent as for groups 1 and 2 and, if they meet
the eligibility criteria, are enrolled into the study.
Outcome measures
The study outcomes are aligned with the categories high-
lighted by CHMP as requiring more research; growth, car-
diovascular system, psychiatric and neurological health16
together with effectiveness of MPH treatment (table 1).
Height velocity, the primary outcome measure on
which the sample size was calculated, was operationa-
lised as height velocity SDS,29 deﬁned as height velocity,
v, estimated from at least two consecutive measurements,
and normalised with reference to the mean and SD of a
population of the same age and sex:
height velocity SDS ¼ v  v
SD
The mean and SD height velocities for each country
represented in the study will be obtained from the most
recent charts available for each country.
Sample size calculation
A variation in instantaneous height velocity SDS of 0.25
is equivalent to a reduction in height velocity of around
0.5 cm/year.29 30 In a sample of 600 treated patients and
300 untreated patients, such a variation can be detected
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with a power of 94% (type 1 error=0.05). Further power
calculations for the secondary outcomes conﬁrmed that
600 medicated patients with ADHD (group 1) and 300
non-medicated patients with ADHD (group 2) will
produce sufﬁcient power to determine the adverse effects
of MPH.
Table 1 Outcome measures
Category Assessment tool Outcomes
Growth and
development
Height measure32 Proportion with height below 2nd centile
Proportion with height below 0.4th centile
Weight measure32 Weight
Proportion with weight below 2nd centile
Proportion with weight below 0.4th centile
Calculated BMI BMI
Proportion with BMI below 2nd centile
Proportion with BMI below 0.4th centile
Tanner pubertal staging33 34 Pubertal stage
Hand X-ray Bone age (substudy)
Cardiovascular system Heart rate32 Proportion with heart rate above 120 bpm
Diastolic blood pressure32 Proportion with diastolic blood pressure above 90 mm Hg
Systolic blood pressure32 Proportion with systolic blood pressure above 95th centile
Psychiatric MFQ39 Assessment of depression.
Total score and proportion above clinical cut-off
PLikS40 Assessment of delusions and hallucinations.
Proportion with definite PLikS and proportion with suspected PLikS
DAWBA modules41 Rapidly changing mood. Proportion above cut-off
Tics section. Proportion above cut-off
Awkward and troublesome behaviour.
Proportion above cut-off
YGTSS42 Proportion reporting motor tics
Proportion reporting phonic tics
C-SSRS63 Proportion reporting any suicidal ideation
Proportion reporting any suicidal behaviour
Proportion reporting each type of behaviour
Number of suicidal behaviours
Lethality of suicidal behaviours
Proportion reporting each type of suicidal ideation
Suicidal ideations severity rating
Suicidal ideation intensity rating
SUQ43 Proportion with any substance use
Proportion with use of specific substances; nicotine,
alcohol, cannabis, other drugs
Neurological CSHQ45 Total score and subscores; proportion above cut-offs
AIMS44 Total score.
Question 8 score
Treatment effectiveness SNAP-IV27 Clinically significant change defined as SNAP total ADHD score <27
CGI35 Global evaluation of severity of symptoms and improvement over
time
CGAS36 Global evaluation of severity of symptoms and improvement over
time
SDQ28 Behavioural screen of emotional symptoms, conduct problems,
hyperactivity/inattention, peer relationship problems and prosocial
behaviour. Total score and proportion above clinical cut-off
DCDQ’0737 Scores motor control, fine motor control and general coordination
SCQ38 Evaluates communication skills and social functioning in children
who may have autism spectrum disorders
ADHD, attention-deficit/hyperactivity disorder; AIMS, Abnormal Involuntary Movement Scale; BMI, body mass index; CGAS, Children’s Global
Assessment; CGI,Clinical Global Impressions; CSHQ, Child’s Sleep Habits Questionnaire; C-SSRS, Columbia-Suicide Severity Rating Scale;
DAWBA, Development and Wellbeing Assessment; DCDQ’07, Developmental Coordination Disorder Questionnaire ’07; MFQ, Mood and
Feelings Questionnaire; PLikS, Psychosis Like Symptoms; SCQ, Social Communication Questionnaire; SDQ, Strength and Difficulties
Questionnaire; SNAP-IV, Swanson Nolan and Pelham IV rating scale; SUQ, Substance Use Questionnaire; YGTSS, Yale Global Tic Severity
Scale.
4 Inglis SK, et al. BMJ Open 2016;6:e010433. doi:10.1136/bmjopen-2015-010433
Open Access
group.bmj.com on September 13, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
To calculate the sample size needed for each group,
the likely attrition rate due to dropouts over the
24-month follow-up period was anticipated to be around
25% based on experience from a previous longitudinal
study of a similar population (ADORE study,31 personal
communication D. Coghill). Thus, the target size is 800
for group 1, 400 for group 2 and 400 for group 3.
Recruitment targets are divided among the four coun-
tries so that each country is required to recruit 200 to
group 1 and 100 to group 3. Since the population of
unmedicated children with ADHD is much larger in
Italy and Hungary compared with that in the UK and
Germany, Italy and Hungary are required to recruit 200
children each to group 2, with the UK and Germany
having no target for this group.
Assessment tools
The assessment tools were chosen to provide outcome
measures in each of the four topic areas identiﬁed by
CHMP as requiring new information,16 together with
outcomes describing the effectiveness of MPH medica-
tion. Details of the assessment tools and the outcomes
associated with each tool are given in table 1. A brief
description is given below.
1. Growth and development: Height and weight will be
measured following the standard operating proce-
dures developed by the Scottish Children’s Research
Network.32 Standardised measures of growth para-
meters at each time point will be calculated accord-
ing to the best available country-speciﬁc norms.
Pubertal maturation will be assessed using the
Tanner scale.33 34 In a subgroup of 70 medicated
Italian participants with ADHD, pubertal staging will
be performed by an expert paediatrician endocrin-
ologist by using Tanner staging of breast development
and pubic hair and by physical examination of tes-
ticle volume using Prader’s orchidometer. The same
patients will undergo an X-ray of the left hand and
wrist for determination of age. Bone age is deter-
mined by comparing each of 20 bonds of an X-ray of
the left hand with the Tanner and Whitehouse atlas,
giving a score to each one and then calculating an
‘age’ from the score of the 20 bones from long bones
(see section Substudy below for additional details). An
assessment of intellectual function will be made at
baseline by determining whether and to what extent
the child receives extra help at school.
2. Psychiatric health: The assessments chosen to assess
psychiatric health are detailed in table 1. The
SNAP-IV27 will be used to measure the ADHD-related
behaviours of participants. The Clinical Global
Impressions (CGI35) and Children’s Global
Assessment Scales (CGAS36) will be used as a second-
ary measure of effectiveness, in particular for ADHD
symptoms. The SDQ is a brief behavioural screening
questionnaire for mental health problems in child-
ren and adolescents aged 3–16 years,28 while the
Developmental Coordination Disorder Questionnaire
(the DCDQ’07) is a brief parent questionnaire
designed to screen for coordination disorders in chil-
dren aged 5–15 years.37 We will also use the Social
Communication Questionnaire (SCQ), which is a
brief parent-rated instrument designed to evaluate
communication skills and social functioning in chil-
dren who may have autism or autism spectrum disor-
ders38 and the Mood and Feelings Questionnaire
(MFQ) Short Version to assess depressive symp-
toms.39 The Psychosis Like Symptoms (PLikS) is a
semistructured instrument that draws on the princi-
ples of the Present State Examination.40 We will be
using an abbreviated version with items relating to
hallucinations and delusions since these are the most
common psychotic symptoms. Modules from the
Developmental and Wellbeing Assessment (DAWBA)
package will be used to screen for the presence of
tics and to rate emotional lability.41 If the DAWBA tics
screen is positive, the Yale Global Tic Severity Scale
(YGTSS) will be used to describe the severity of the
tics and the level of impairment they impart.42 Suicidal
ideation and behaviour will be measured using the
Columbia—Suicide Severity Rating Scale (C-SSRS,
Kelly Posner, personal communication), which is the
instrument recommended by the Food and Drugs
Administration (FDA) in child and adolescent clinical
trials. Any substance misuse will be assessed using the
Substance Use Questionnaire (SUQ), developed for
use in the Multimodal Treatment study of children
with ADHD (MTA).43
3. Neurological health: Two tools will be used to assess
neurological health: the Abnormal Involuntary
Movement Scale (AIMS) to measure dyskinesias44
and the Child’s Sleep Habits Questionnaire (CSHQ)
to assess sleep difﬁculties.45
4. Cardiovascular health: To assess cardiovascular health,
blood pressure will be measured at each visit follow-
ing the standard operating procedure developed by
the Scottish Children’s Research Network32 and
recorded as age-adjusted and height-adjusted cen-
tiles.46 A brief cardiac examination will also be per-
formed by a clinician at the ﬁrst study visit (table 2).
A more detailed study of the effects of long-term use
of MPH on cardiovascular health in a separate
cohort of children and adolescents will also be
carried out by the ADDUCE consortium. This separ-
ate study will be described elsewhere.
5. Effectiveness: The effectiveness of MPH treatment will
be assessed using the tools described in table 1.
Together with these assessments, demographic data
and information about the medical and psychiatric his-
tories of the participant and their relatives will be col-
lected (table 3).
Assessment schedule
Participants in all three groups will undergo the same
assessments, at six-monthly intervals for 2 years, so that
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they have ﬁve study visits in total (ﬁgure 1). Participants
in the medicated ADHD group (group 1) will have their
ﬁrst assessment before they begin MPH treatment. The
study visits can be carried out during an 8-week period
around the date that the visit is due, maximising the
opportunity for the visit to take place. Assessments of all
primary and secondary measures will be made at each
study visit, with the exception of the visit at 18 months at
which only the height, weight, blood pressure, vital signs
and pubertal maturation will be assessed, and medica-
tion history updated (table 4).
Study set up
The lead country for the study is the UK, with sponsor-
ship provided by Tayside Medical Science Centre
(TASC), a joint partnership of National Health Service
(NHS) Tayside and the University of Dundee.47 Patient
information leaﬂets and consent forms were translated
as necessary in each country and submissions were
then made by each of the other three countries to
secure ethical permission at their own sites. Overall
management of the trial is being provided by the
Tayside Clinical Trials Unit (TCTU), a UK Clinical
Table 2 Cardiac examination
Inspection
Look at the participant Comfortable at rest, cyanosis, breathless, scars, syndromes
(eg, Marfan’s, Down’s, Turner’s)
Look at the hands Clubbing, peripheral cyanosis
Feel the radial pulse Assess rate (over 15 s) and rhythm (sinus, regularly irregular or
irregularly irregular)
Palpation
Feel for the apex beat Usually in the 5th intercostal space in the midclavicular line.
Auscultation
Simultaneously listen and palpate a pulse (preferably a central pulse) to time any murmur to the cardiac cycle
Listen over the apex beat (mitral area) with the bell,
and then the diaphragm
Listen for heart sounds 1 and 2 (and 3 and 4), systolic and
diastolic murmurs
Listen over the left sternal edge in the 4th intercostal
space (tricuspid area)
Listen for heart sounds 1 and 2, systolic and diastolic murmurs
Listen over the left sternal edge in the 2nd intercostal
space (pulmonary area)
Listen for heart sounds 1 and 2, systolic and diastolic murmurs
Listen over the right sternal edge in the 2nd intercostal
space
Listen for heart sounds 1 and 2, systolic and diastolic murmurs
Measure blood pressure
A brief cardiac examination will be conducted to include.
Table 3 Assessment of demographic details and family history
Demographics Age
Sex
Nationality
Ethnicity
Siblings
Marital status of parents
Type of family home
Personal history Birth weight
Gestational age at delivery
Intellectual functioning
Physical health (history of syncope, head injury, seizures, genetic syndromes, cardiac problems,
hypertension, diabetes, asthma or epilepsy)
Psychological health (axes 1 and 2 mental disorders)
Medication history Past psychiatric medications (name, dose, frequency, date started, date stopped)
Current psychiatric medications (name, dose, frequency, date started)
Other current medications (name, dose, frequency, date started)
Allergies or sensitivity to medication
Psychiatric medication started at study visit (name, dose, frequency)
Reported concordance with current medications
Family history Physical health (cardiac problems, hypertension, diabetes, asthma or epilepsy)
Psychological health (axes 1 and 2 mental disorders)
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Research Collaboration (UKCRC)-registered clinical
trials unit.47
Study-speciﬁc training was given to lead representa-
tives of all sites at an initial set-up meeting. A training
package was developed on the basis of that meeting and
provided to all researchers working on the study.
The design of the project enables the study to be run
differently in the four participating countries, within the
boundaries of the study protocol. Each country has a
lead site which coordinates and supports the study at the
other sites within that country.
Training and quality control across sites
To ensure that the data collected from the study are of
the highest quality, the ADDUCE study is being con-
ducted to standards that accord with GCP guidelines.48
A number of measures have been put in place to ensure
that the data are of high quality and are collected in a
consistent way across all sites. These include a compre-
hensive training package which includes audio and
video records of the initial training meeting and will be
completed by all researchers before they begin work on
the study. Additionally, training meetings have been held
in each country for which there is more than one site,
to ensure that information is disseminated from the lead
sites to their satellite sites, and there is good communi-
cation between sites in each country. This communica-
tion will be maintained throughout the study period
through regular teleconferences, emails and face-to-face
meetings. Finally, the trial manager located in Dundee
will oversee the work at all sites, ensuring that all sites
are adhering to the research governance regulations, are
collecting good-quality data and are entering those data
into the electronic data management system correctly.
Substudy
As a complementary part of the present 2-year naturalis-
tic pharmacovigilance European multicentre study, a
speciﬁc substudy within the ADDUCE project will con-
tribute to evaluate the long-term effects of MPH on
growth and pubertal maturation.
Poor growth is a common concern related to stimulant
medications, especially with children already on the
lower growth percentiles. Studies providing longitudinal
data indicate a reduction in height and weight gain;
these effects are usually minimal, but there is substantial
variability with some children being completely
unaffected, whereas others show signiﬁcant growth sup-
pression.49–51 Early studies have suggested that ﬁnal adult
height is not affected by administration of psychostimu-
lants;52 53 nevertheless, follow-up periods are often not
sufﬁciently long enough to allow ﬁrm conclusions to be
drawn and these studies do not appear to consider the
effect of puberty on growing processes and were not nor-
malised for pubertal stage.
Within the Italian medicated cohort, 70 medicated
Italian patients with ADHD, aged 6–12, will be assessed by
an accurate assessment of growth parameters and pubertal
staging performed by an expert paediatrician endocrinolo-
gist. The monitoring of bone age will also be explored
as a possible helpful tool, adding value to the routine
measures of growth. Bone age is regarded as the gold
standard to evaluate the ‘growing power’ of an individ-
ual and represents a major tool to calculate expected
ﬁnal height. The sample size of N=70 has been calcu-
lated as for an exploratory study. The paucity of previ-
ous data about X-rays in this population and its cost
prevented the procedure being extended to the entire
sample. The number of 70 has been therefore consid-
ered sufﬁcient to provide general information in order
to evaluate the validity of this tool.
Measurements of bone age at baseline allow calcula-
tion of the expected ﬁnal height using the methods of
Tanner et al.54 Subsequent yearly measurements will allow
calculation of the rate of bone maturation. Bone age/
chronological age ratio is related to the growth potential
of a child; an increase of the ratio is negatively related to
the predicted ﬁnal and adult height. Therefore, a
decrease in height velocity with no decrease in bone mat-
uration rate will reduce the ﬁnal expected height and
may result in short stature; hence, it will represent an
adverse outcome on growth. An increase in the differ-
ence (bone age−chronological age) ≥ ±6 months (+1
SD) is deemed clinically signiﬁcant, representing a
change in a child’s growing potential.
The radiological risk related to X-ray of the left hand
is very low, equivalent to a 2-week stay at a mountain or
seaside area.55 The child will not be exposed to the risk
of a cumulative effect of radiation because the time
interval between two radiograms is long enough.
Data collection and management
Data collected at each study visit will be entered into a
paper case report form (CRF). The data will
Figure 1 Study design flow
chart.
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subsequently be entered into an electronic version of
the CRF (eCRF) at each site. The eCRF was developed
by the Health Informatics Centre (HIC) at the
University of Dundee56 using Openclinica open source
software.57
Primary outcome data entered into the database will
be veriﬁed against source data in the paper CRFs. A
proportion of secondary outcome data will also be veri-
ﬁed depending on the resources available.
Analysis plan
Description at baseline
Characteristics of participants included in the study will
be presented using the ‘five number summary’
Table 4 Schedule of study visits and assessments
Screen Visit 1
Visit 2
6-month
Visit 3
12-month
Visit 4
18-month
Visit 5
24-month
Visit
Visit schedule
Week
-4-0
Baseline
Week 0
Weeks
22–30
Weeks
48–56
Weeks
74–82
Weeks
100–108
Informed consent/assent ✓ or ✓
Inclusion/exclusion criteria ✓ or ✓
Demographics ✓
Family medical and psychiatric history ✓
Child medical and psychiatric history ✓
Developmental history ✓
Medication history and current medications ✓
Psychiatric medication (s) Prescribed or
continued at visit (including drug and dose
and concordance)
✓ ✓ ✓ ✓ ✓
Other medication since last visit ✓ ✓ ✓ ✓
Learning difficulties ✓
Cardiac examination ✓
Vital signs ✓ ✓ ✓ ✓ ✓
Height ✓ ✓ ✓ ✓ ✓
Weight ✓ ✓ ✓ ✓ ✓
BMI ✓ ✓ ✓ ✓ ✓
Parental height ✓
Target height ✓
Calculation of predictive definitive height value
(Tanner-Whitehouse method)
✓
Pubertal maturation ✓ ✓ ✓ ✓ ✓
SNAP-IV ✓ ✓ ✓ ✓
CGI-S ✓ ✓ ✓ ✓
CGI-I ✓ ✓ ✓
CGAS ✓ ✓ ✓ ✓
DCDQ’07 ✓ ✓
SCQ ✓ ✓
SDQ ✓ ✓ ✓ ✓
AIMS ✓ ✓ ✓ ✓
CSHQ ✓ ✓ ✓ ✓
MFQ-P (parent version) ✓ ✓ ✓ ✓
MFQ-C (self-report version) ages≥8 years ✓ ✓ ✓ ✓
PLikS ✓ ✓ ✓ ✓
DAWBA Tics ✓ ✓ ✓ ✓
YGTSS ✓ ✓ ✓ ✓
DAWBA rapidly changing mood (parent
version)
✓ ✓ ✓ ✓
DAWBA rapidly changing mood (child version) ✓ ✓ ✓ ✓
DAWBA awkward and troublesome behaviour ✓ ✓ ✓ ✓
C-SSRS (baseline) ✓
C-SSRS (since last seen) ✓ ✓ ✓
Substance use questionnaire ✓ ✓ ✓ ✓
AIMS, Abnormal Involuntary Movement Scale; BMI, body mass index; CGAS, Children’s Global Assessment; CGI, Clinical Global
Impressions; CSHQ, Child’s Sleep Habits Questionnaire; C-SSRS, Columbia-Suicide Severity Rating Scale; DAWBA, Development and
Wellbeing Assessment; DCDQ’07, Developmental Coordination Disorder Questionnaire ’07; MFQ, Mood and Feelings Questionnaire;
PLikS, Psychosis Like Symptoms; SCQ, Social Communication Questionnaire; SDQ, Strength and Difficulties Questionnaire;
SNAP-IV, Swanson Nolan and Pelham IV rating scale; YGTSS, Yale Global Tic Severity Scale.
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(minimum, maximum, lower and upper quartiles and
median) for the quantitative variables, and percentages
for categorical variables. The whole sample and each of
the three groups will be presented in this way.
Traditional trivariate/bivariate comparisons will be
carried out to compare the groups (eg, analysis of vari-
ance (ANOVA), χ2 tests or non-parametric tests, ac-
cording to their conditions of validity). Graphical
representations will be used to characterise distributions
(histograms, density plots, box plots) or to explore pat-
terns of association of covariates (multidimensional
exploratory graphical methods). When participants
change their status, their data will be censored for
analyses.
Longitudinal description
The evolution of data with time will be graphically and
numerically presented. This part is essential, in particu-
lar to design the mixed models used to analyse the
primary end point (see below).
Incidence rates and relative risk
These will be estimated according to the number of
participant-years available in the study at the time of ana-
lysis. For a given participant, only the ﬁrst occurrence of
a side effect will be considered. Incidence rates will be
estimated in each of the three groups.
Bivariate analysis
The association with the primary and secondary end
points will be statistically tested with all potential covari-
ates of interest (including time on drug and dose and
duration of treatment) using traditional procedures (eg,
correlations, ANOVA, χ2 tests or non-parametric tests
according to conditions of validity). These tests will be
regarded as strictly exploratory.
Analysis of primary end point
The child’s height velocity will be estimated from all
available data using a simple linear regression of height
with time (one linear regression for each participant).
Child’s height velocity and child’s height velocity SDS
will thus be available only for participants having at least
two visits. The distribution of height velocity SDS will be
carefully examined (density plot with standardised
normal plot). If this distribution is normal, a mixed
model for normal outcome will be used. The primary
predictor variable will be ‘group’ (medicated ADHD,
unmedicated ADHD, non-ADHD controls). The covari-
ates will be:
1. Three propensity scores contrasting each of the three
pairs of group categories (ie, medicated vs unmedi-
cated, medicated vs non-ADHD, unmedicated vs
non-ADHD). These propensity scores will be esti-
mated from a logistic regression incorporating all
available data (at the condition of convergence of
the maximum likelihood estimator). A regression
spline between height velocity SDS and each of the
three logistic scores will help to determine how these
propensity scores will be introduced in the model
(linear, polynomial, deciles, etc). The propensity
scores will be estimated after imputing missing data
using a Gibbs sampler.
2. ‘Family’ as a random effect (to take into account the
pairing of groups medicated ADHD and non-
medicated sibling).
3. ‘Country’.
4. ‘Duration of treatment’.
Additional adjustment for potential confounders, or
adjustment by inclusion of variables (measured at base-
line) that are considered essential (because of their clin-
ical relevance, because of the bivariate analysis or
because the propensity scores were unsuccessful in sup-
pressing the imbalance between groups for a given cov-
ariate), may also be necessary.
No adjustment of p values for inclusion of multiple
covariates will be carried out, since the primary hypoth-
esis concerns the effect of the ‘group’ variable, and
since in a pharmacovigilance study statistical power is at
least as important as type one error.
The effect of the ‘group’ variable will be assessed glo-
bally, then with planned contrasts comparing medicated
versus unmedicated, and medicated versus non-ADHD.
Missing data in adjustment covariates will be imputed
using a Gibbs sampler (simple imputation because infer-
ential statistics especially concern the variable ‘group’)
Regression diagnostics will be performed.
Interaction terms, for example, age and sex, will be
tested one at a time to look for speciﬁc populations at
risk.
If the height velocity SDS is not normally distributed,
linearising transformations will be tried (log, box-cox,
etc). If no transformation is possible, a bootstrap proced-
ure will be used.
Finally, sensitivity analyses will be conducted to test the
robustness of the results, for example, removal of
patients who switch treatment and patients with concur-
rent psychotropic drugs.
Ethics and dissemination
The study will be conducted according to the principles
of the Declaration of Helsinki58 and in accordance with
the Research Governance Framework Scotland and
other appropriate guidelines and regulations in each
country.59 Since the study is purely observational, there
are no anticipated extra risks to participants. Results will
be disseminated through peer-reviewed publications and
a lay summary of the results will be posted on the study
website.
MPH is recommended as the ﬁrst choice medication
for ADHD and is the most frequently used in Europe.3
Despite the evidence of positive effects of stimulants on
the core symptoms of ADHD supported by numerous
studies,20 60 many unanswered questions remain about
the underlying biological mechanism and the mediators
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and moderators of possible adverse effects as the ones
emphasised by CHMP and objectives of this project.
At present, a guidelines group of the European
Network for Hyperkinetic Disorders (EUNETHYDIS)
recommends careful physical assessment of children and
adolescents before and during chronic treatment with
psychostimulants.61 With regard to the possible effects
on growth, it is highly recommended to assess growth
parameters before stimulant treatment with periodic
monitoring through repeated measurements of weight
and height and their changes over time (at least three
or four times per year). Likewise, pretreatment checking
and monitoring of pulse and blood pressure are also
recommended with ADHD medication, with frequency
of monitoring either three-monthly62 or six-monthly.3
Blood pressure recorded as a centile score allows appro-
priate referral to a paediatric hypertension expert when
at least two consecutive recordings are above the 95th
centile. When the pulse rate is consistently above 120/
min, a referral to a paediatric cardiologist is appropriate.
According to the same guidelines, a careful monitoring
of psychiatric and neurological potential adverse effects
is also recommended.
In this context, the ADDUCE project, with a long
follow-up period and a rigorous methodology, will provide
important information about the safety of psychostimulant
medications within the ADHD population, covering
various aspects of potential adverse events in children and
adolescents with a range of different ADHD symptoms.
The project will also help in understanding and answering
the present unsolved questions about underlying bio-
logical mechanisms including possible mediators, modera-
tors and confounders such as clinical and demographic
characteristics and medication factors (average daily dose,
cumulative dosage of MPH, pretreatment history of medi-
cation, use of co-medication). We expect that ADDUCE
will also have an impact on research in paediatric psycho-
pharmacology by establishing a collaborative network of
expert centres, and that the dissemination of results will
lead to improved standards of care and management of
ADHD through the development of guidelines for a com-
prehensive personalised monitoring of treatment.
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